In melanoma cells with BRAF mutations, PD-L1 expression is promoted through the activation of STAT3 and the downstream MAPK signal c-Jun, using MEK inhibitors significantly downregulates MAPK signaling and suppresses the production of PD-L1 [236]. Here, STAT3 is linked to melanoma.